Gilead Sciences, Inc. (NASDAQ:GILD) Q3 2023 Earnings Conference Call November 7, 2023 4:30 PM ET Company Participants Jacquie Ross - Vice President, Investor Relations Daniel O'Day - Chairman and Chief Executive Officer Johanna Mercier - Chief Commercial Officer Merdad Parsey - Chief Medical Officer Andrew Dickinson - Chief Financial Officer Cindy Perettie - Executive Vice President, Kite Conference Call Participants Geoff Meacham - Bank of America Michael Yee - Jefferies Daina Graybosch - Leerink Partners ...

Q323 Financial Results November 7, 2023 Forward-Looking Statements Statements included in this presentation that are not historical in nature are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Gilead cautions readers that forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include those relating to: Gilead's ability to achieve its anticipated full ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File No. 0-19731 GILEAD SCIENCES, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 94-3047598 (State or Other Jur ...

https://reportify-1252068037.cos.ap-beijing.myqcloud.com/media/production/s_m_content_4480560867daa7897cdca7c4f81be1aa.html ...

Summary of Gilead Sciences, Inc. Conference Call Company Overview - **Company**: Gilead Sciences, Inc. (NASDAQ: GILD) - **Date**: September 6, 2023 - **Participants**: Andrew Dickinson (CFO), Mohit Bansal (Wells Fargo Analyst) Key Points on HIV Business - **Market Growth**: The HIV treatment market is growing at a rate of 2% to 3% annually in the US, with the prevention market experiencing a significant growth of approximately 20% over the last couple of years [4][5] - **Product Performance**: Descovy holds over 40% of the HIV prevention market in the US, indicating strong commercial performance despite competition from generics [7] - **Long-Acting Therapies**: Gilead is developing lenacapavir, a novel HIV capsid inhibitor, which is expected to change the prevention market dynamics by ensuring better adherence and compliance [7][9] - **Future Outlook**: The HIV treatment franchise, including Biktarvy and Descovy, is expected to continue growing through the end of the decade and beyond, despite concerns about generics entering the market [11] Key Points on Oncology Business - **Market Position**: Gilead's oncology business is currently valued at $3 billion and is expected to grow rapidly, with significant advancements in cell therapy and antibody-drug conjugates [20] - **TRODELVY Performance**: The combination of TRODELVY with PD-1 therapy showed a response rate of approximately 70% in high PD-L1 expressers, significantly higher than the standard of care [20][21] - **Safety Profile**: TRODELVY has a well-defined safety profile, which is crucial for its acceptance in first-line therapies [23] - **TIGIT Development**: Gilead's TIGIT antibody is expected to provide additive benefits when combined with PD-1 therapies, with ongoing studies to validate its efficacy [26] Financial and Strategic Insights - **R&D and SG&A Spending**: Gilead has increased its R&D and SG&A spending to support its growth ambitions, aligning its spending levels with industry benchmarks [30] - **Operating Margins**: Despite increased spending, Gilead maintains one of the strongest operating margins in the industry, with expectations for continued growth in EPS [30] - **Business Development Strategy**: Gilead is focusing on earlier-stage deals to fill its pipeline, indicating a strategic shift towards maintaining a robust portfolio without the need for large acquisitions [32][33] Additional Insights - **Market Dynamics**: The shift towards long-acting therapies in both treatment and prevention is expected to significantly expand the market, particularly in HIV prevention [15][16] - **Compliance Issues**: Compliance remains a challenge in both treatment and prevention settings, highlighting the importance of developing therapies that ensure adherence [18] - **Future Data Releases**: Upcoming data releases, particularly for EVOKE-02 and other clinical studies, are anticipated to provide further insights into Gilead's product efficacy and market positioning [19][20] This summary encapsulates the key insights from the conference call, focusing on Gilead's strategic direction, market performance, and future growth potential in both the HIV and oncology sectors.

Gilead Sciences, Inc. (NASDAQ:GILD) Q2 2023 Earnings Conference Call August 3, 2023 5:00 PM ET Company Participants Jacquie Ross - Vice President, Investor Relations Daniel O'Day - Chairman and Chief Executive Officer Johanna Mercier - Chief Commercial Officer Merdad Parsey - Chief Medical Officer Andrew Dickinson - Chief Financial Officer Cindy Perettie - Executive Vice President, Kite Conference Call Participants Geoff Meacham - Bank of America Chris Schott - JPMorgan Tyler Van Buren - TD Cowen Terrence F ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File No. 0-19731 GILEAD SCIENCES, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 94-3047598 (State or Other Jurisdic ...

Gilead Sciences, Inc. (NASDAQ:GILD) Goldman Sachs 44th Annual Global Healthcare Conference June 12, 2023 1:40 PM ET Company Participants Daniel O’Day - Chairman & CEO Merdad Parsey - Chief Medical Officer Conference Call Participants Salveen Richter - Goldman Sachs Salveen Richter Great. Good morning, everyone. Thanks for joining us. I’m Salveen Richter, Biotechnology Analyst at Goldman Sachs, and we're really pleased to have Gilead with us. So we have Dan O’Day, Chairman and CEO as well as Merdad Parsey, C ...

Gilead Sciences, Inc. (NASDAQ:GILD) Jefferies Global Healthcare Conference June 7, 2023 11:00 AM ET Company Participants Johanna Mercier - Chief Commercial Officer Conference Call Participants Michael Yee - Jefferies Michael Yee Thank you very much. I want to get started on the next session. It's Michael Yee, Managing Director. I'm the senior biotechnology analyst at Jefferies. I'm very happy to have with us here at Gilead Sciences, Johanna Mercier, the Chief Commercial Officer. And I thought that would be ...

Gilead Sciences, Inc. (NASDAQ:GILD) RBC Capital Markets Global Healthcare Conference May 16, 2023 11:00 AM ET Company Participants Merdad Parsey - Chief Medical Officer Conference Call Participants Brian Abrahams - RBC Capital Markets Brian Abrahams Good morning. I'm Brian Abrahams, one of the senior biotech analysts here at RBC Capital Markets, and welcome again. Our next presenting company is Gilead. Really pleased to have with us their Chief Medical Officer, Merdad Parsey. Merdad, thank you again. Merdad ...